Anterix rated neutral after a 5x YTD rally; a $110 FY2027 target implies 4% upside. Click for more on ATEX stock.
On the heels of a big launch for its new James Bond video game, “007 First Light,” and talks of another 007 film, Amazon is ...
Industrial bellwether Dover (NYSE:DOV | DOV Price Prediction) has spent the year shrugging off recession chatter while ...
Vera Therapeutics' Trutakna received an early, fast-tracked approval from the FDA to reduce proteinuria in adults with ...
The May 8 fire ignited in a section of the Chalmette Refining complex where impurities are removed from oil constituents to ...
Interesting Engineering on MSN
Japanese catalyst keeps CO₂-to-methanol byproducts below 11 percent
Scientists in Japan have recently developed a copper nanocluster that can convert carbon dioxide ...
7hon MSN
SpaceX Is Quickly Entering Index Funds. Will OpenAI and Anthropic do the Same After Their IPOs?
SpaceX's fast move into index funds could reshape how investors think about future AI IPOs.
Trimble is evolving into a software-driven, recurring-revenue business. Click here to read why I would rate TRMB stock a Buy.
The vacant Charleston Pepsi bottling plant that was built in the 1960s has been sold again, this time for $13.5 million to an ...
Shares of Cloudflare (NYSE:NET | NET Price Prediction) are up 9% in midday trading to about $269 after Scotiabank upgraded ...
As the 2026 FIFA World Cup unfolds across North America, the global spotlight once again falls on football’s greatest stage.
Newsable Asianet News on MSN
AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism
Agios said the U.S. Food and Drug Administration granted Priority Review to its supplemental new drug application for Mitapivat in sickle cell disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results